Handbook of solubility data for pharmaceuticals , Handbook of solubility data for pharmaceuticals , کتابخانه دیجیتال جندی شاپور اهواز

http://chemistry-chemists.com/chemister/Spravochniki/handbook-of-solubility-data-for-pharmaceuticals-2010.pdf

Handbook of Solubility Data for Pharmaceuticals

As a novel class of porous crystalline materials, hydrogen-bonded organic frameworks (HOFs), self-assembled from organic or metal-organic building blocks through intermolecular hydrogen-bonding interactions, have attracted more and more attention. Over the past decade, a number of porous HOFs have been constructed through judicious selection of H-bonding motifs, which are further enforced by other weak intermolecular interactions such as π-π stacking and van der Waals forces and framework interpenetration. Since the H-bonds are weaker than coordinate and covalent bonds used for the construction of metal-organic frameworks (MOFs) and covalent organic frameworks (COFs), HOFs have some unique features such as mild synthesis condition, solution processability, easy healing, and regeneration. These features enable HOFs to be a tunable platform for the construction of functional materials. Here, we review the H-bonding motifs used for constructing porous HOFs and highlight some of their applications, including gas separation and storage, chiral separation and structure determination, fluorescent sensing, heterogeneous catalysis, biological applications, proton conduction, photoluminescent materials, and membrane-based applications.

Hydrogen-Bonded Organic Frameworks as a Tunable Platform for Functional Materials.

The 31 P NMR spectra of triethylphosphine oxide (Et 3 PO) undergoes a shift upon interaction in solution with adjacent molecules. The oxygen of Et 3 PO is a strong electron donor and readily forms acid-base complexes with electron acceptors, with a consequent downfield shift in the 31 P NMR spectrum (Δδ ab ). We find that the 31 P NMR spectrum also is shifted downfield appreciably by van der Waals (largery dispersion force) interactions with solvents (Δδ d )

Spectral shifts in acid-base chemistry. II: Van der Waals contributions to acceptor numbers

An analytical model for spontaneous imbibition in fractal porous media including gravity

Poly(lactic acid) (PLA) is the most used biopolymer for food packaging applications. Several strategies have been made to improve PLA properties for extending its applications in the packaging field. Melt blending approaches are gaining considerable interest since they are easy, cost-effective and readily available processing technologies at the industrial level. With a similar melting temperature and high crystallinity, poly(hydroxybutyrate) (PHB) represents a good candidate to blend with PLA. The ability of PHB to act as a nucleating agent for PLA improves its mechanical resistance and barrier performance. With the dual objective to improve PLAPHB processing performance and to obtain stretchable materials, plasticizers are frequently added. Current trends to enhance PLA-PHB miscibility are focused on the development of composite and nanocomposites. PLA-PHB blends are also interesting for the controlled release of active compounds in the development of active packaging systems. This review explains the most relevant processing aspects of PLA-PHB based blends such as the influence of polymers molecular weight, the PLA-PHB composition as well as the thermal stability. It also summarizes the recent developments in PLA-PHB formulations with an emphasis on their performance with interest in the sustainable food packaging field. PLA-PHB blends shows highly promising perspectives for the replacement of traditional petrochemical based polymers currently used for food packaging.

On the Use of PLA-PHB Blends for Sustainable Food Packaging Applications

The invention relates to a ginsenoside C-K semihydrate crystal and a preparation method thereof The raw material of ginsenoside C-K is added into a mixed solvent of acetone and water, a cooling crystallization method is adopted, seed crystals are added into the supersaturated solution of the ginsenoside C-K during cooling and induced to form crystals, the core formation of the crystals is controlled, and the growth of the crystals is promoted The 2 theta values corresponding to the powder diffraction characteristic peaks of the obtained ginsenoside C-K semihydrate crystal are 54+/-02, 66+/-02, 110+/-02, 126+/-02, 132+/-02, 145+/-02, 155+/-02, 159+/-02, 171+/-02 and 206+/-02 According to the invention, the ginsenoside C-K semihydrate crystal is prepared via the cooling crystallization method, and the crystallization yield of C-K is improved; and the core formation generated during crystallization is avoided, and a product with uniformly distributed granularity and stability is obtained

Ginsenoside C-K semihydrate crystal and preparation method thereof

The invention provides a clindamycin phosphate dimethyl sulfoxide solvent compound crystal and a preparation method thereof. The crystal is the clindamycin phosphate dimethyl sulfoxide solvent compound crystal; 1 molecule of the clindamycin phosphate dimethyl sulfoxide solvent compound crystal comprises 1 molecule of clindamycin phosphate and 1 molecule of dimethyl sulfoxide. The preparation method comprises the following steps of: dissolving crude clindamycin phosphate into a mixed solvent of deionized water and the dimethyl sulfoxide, wherein the volume concentration of initial clindamycin phosphate is 0.05-0.08 g/mL; heating and stirring a solution till the solution is dissolved, carrying out hot filtration, placing filter liquor in a room temperature environment, and slowly evaporating till white crystalline solids appear; filtering to obtain the clindamycin phosphate dimethyl sulfoxide solvent compound crystal. The clindamycin phosphate dimethyl sulfoxide solvent compound has good stability property; after the clindamycin phosphate dimethyl sulfoxide solvent compound is placed at a high temperature of 60 DEG C for 10 days, the crystal is stable, the crystal is kept as white powder, and an X-ray X-ray diffraction pattern is not obviously changed.

Clindamycin phosphate dimethyl sulfoxide solvent compound crystal and preparation method thereof

In the title complex, {[Ag(C13H13NS2)]BF4}n, the AgI ions show linear coordination through the N atom from one 1-phenyl­sulfanyl-2-(2-pyridylsulfan­yl)ethane (L) mol­ecule and the S atom of another. Each L ligand bridges two adjacent Ag atoms through the donor mol­ecules, leading to a linear chain structure.

catena-Poly[[silver(I)-μ-1-phenyl­sulfanyl-2-(2-pyridylsulfan­yl)ethane-κ2S1:N2] tetra­fluoro­borate]

The invention relates to irbesartan hydrobromide and a preparation method thereof; irbesartan and solvent are mixed to prepare into solution or suspension liquid, and the mass ratio of the solvent volume and the irbesartan is 1-10mL/g; and then the solution or suspension liquid is mixed with hydrobromic acid solution, and the mass ratio of the hydrobromic acid in the hydrobromic acid solution andthe irbesartan is 1:26-53; the mixture is stirred continuously, after the solution is settled, elution agent is dropwise added, the volume ratio of the elution agent and the solvent is 1-10:1, seedcrystal is added or crystal growing is carried out after crystal generation is carried out spontaneously, after the elution agent is dropwise added, crystal mush is washed and dried to obtain the irbesartan hydrobromide after solid-liquid separation is carried out The irbesartan hydrobromide obtained in the invention has adjustable granularity, concentrated granularity distribution, bright and clean surface, good product mobility, high crystallinity and low static electricity property, and is beneficial to industrial operation; in addition, the product has stable performance, is hard to be decomposed and is convenient for storage and transportation and usage

Irbesartan hydrobromide and preparation method thereof

The invention provides a clindamycin phosphate methanol-water solvent compound crystal and a preparation method thereof. The crystal is the clindamycin phosphate methanol-water solvent compound crystal. 1 molecule of the clindamycin phosphate methanol-water solvent compound crystal comprises 1 molecule of clindamycin phosphate, 1 molecule of methanol and 2 molecules of water. The preparation method comprises the following steps of: dissolving crude clindamycin phosphate into a mixed solvent of deionized water and methanol, wherein the mass concentration of initial clindamycin phosphate is 0.09-0.12 g/mL; heating and stirring a solution till the solution is dissolved, carrying out hot filtration, placing filter liquor in a room temperature environment, and slowly evaporating for the time from 5 days to 7 days till white crystalline solids appear; filtering to obtain the clindamycin phosphate methanol-water solvent compound crystal. The crystal has good stability property; the clindamycin phosphate methanol-water solvent compound crystal is placed under the condition of normal temperature at 30 DEG C for 10 days, and X-ray powder diffraction is measured by respectively sampling at the 5th day and the 10th day to judge the stability condition of the crystal.

Baohong Hou

Papers

Ginsenoside C-K semihydrate crystal and preparation method thereof

Clindamycin phosphate dimethyl sulfoxide solvent compound crystal and preparation method thereof

catena-Poly[[silver(I)-μ-1-phenylsulfanyl-2-(2-pyridylsulfanyl)ethane-κ2S1:N2] tetrafluoroborate]

Irbesartan hydrobromide and preparation method thereof

Clindamycin phosphate methanol-water solvent compound crystal and preparation method thereof

Baohong Hou

Papers

Ginsenoside C-K semihydrate crystal and preparation method thereof

Clindamycin phosphate dimethyl sulfoxide solvent compound crystal and preparation method thereof

catena-Poly[[silver(I)-μ-1-phenyl­sulfanyl-2-(2-pyridylsulfan­yl)ethane-κ2S1:N2] tetra­fluoro­borate]

Irbesartan hydrobromide and preparation method thereof

Clindamycin phosphate methanol-water solvent compound crystal and preparation method thereof

catena-Poly[[silver(I)-μ-1-phenylsulfanyl-2-(2-pyridylsulfanyl)ethane-κ2S1:N2] tetrafluoroborate]